Ladero JM, Cárdenas MC, Ortega L, González-Pino A, Cuenca F, Morales C, Lee-Brunner A

Idioma: Ingles.
Referencias bibliográficas: 16
Paginas: 648-651
Archivo PDF: 84.00 Kb.

RESUMEN

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 5: 52-64.

2. Gressner AM, Gao C-F, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009; 15: 2433-40.

3. Ladero JM. Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. Hepat Mon 2011; 11: 698-700.

4. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med 1999; 37: 389-95.

5. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605-13.

6. Gerbes AL, Gülberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-10.

7. Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, Burns A, et al. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-78.

8. Takeuchi M, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2001; 13: 951-5.

9. Chu S-C, Wang C-P, Chang Y-H, Hsieh YS, Yang SF, Su JM, Yang CC, et al. Increased cystatin C serum concentrations in patients with hepatic deisease of various severities. Clin Chim Acta 2004; 341: 133-8.

10. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.

11. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

12. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.

13. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurisms. J Clin Invest 1999; 104:1191-7.

14. Gressner AM, Lahme B, Meurer SK, Gressner O, Weiskirchen R. Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. World J Gastroenterol 2006; 12: 731-8.

15. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, et al. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-36.

16. Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, et al. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009; 29: 1521-7.